Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ADXS-504, a Cancer Type Specific Immunotherapy, With Biochemically Recurrent Prostate Cancer

NCT05077098 is registered in ClinicalTrials.gov with Mark Stein as lead sponsor.

NCT NCT05077098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ADXS-504, a Cancer Type Specific Immunotherapy, With Biochemically Recurrent Prostate Cancer
Lead sponsor
Mark Stein
Phase
Phase 1
Overall status
Completed
Start date
August 12, 2021
Completion date
April 10, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent prostate cancer